2021 Cross-Border Healthcare Innovation & Partnership Summit

(MSQ Ventures & Bayhelix)

MSQ Ventures is hosting its 2021 Cross-Border Healthcare Innovation & Partnership Summit, a Virtual event on September 23rd and 24th, together with BayHelix Group. Our partner BayHelix Group is a non-profit organization that connects emerging biopharmaceutical companies in China, with over 800 members globally and over two-thirds of members are C-level executives. The 2-day conference will invite top industry experts to share the most cutting-edge technical information, interpret the latest industrial policies, and fully link the multi-platform of industry, research and investment.

We sincerely invite you to join us in September to participate in this grand event!

Conference Details

  • Time: 9 am- 12 pm China time (GMT+8), September 23rd and 24th, 2021

  • Organizers: MSQ Ventures

  • Co-organizer: BayHelix Group

  • Meeting Format: Virtual

  • Register here

Agenda-At-a-Glance

Panel Discussion: China for Global: Out-licensing opportunities, challenges, and perspectives

9:10 am- 10:00 am China time, Sept 23rd (Thursday), 2021

Most Recent Deals:

Aug 9th, 2021: Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

Aug 17th, 2021: Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China

July 12th, 2021: Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Feb 1st, 2021: Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

Dec 16th, 2020: Harbour BioMed Out-Licenses SARS-COV-2 Antibody to AbbVi

Sept 4th, 2020: AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

June 5th, 2020: AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19

June 1st, 2020: AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

March 30th, 2020: I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology

Jan 13th, 2020: Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

Panel Discussion: Cross-border Collaboration Opportunites: unmet medical needs and emerging technologies in China

10:00 am- 10:50 am China time, Sept 23rd (Thursday), 2021

Expert Speech: How to monitor pharmaceutical patent listing and generic challenge under China’s patent linkage system

9:05 am - 10:05 am China time, Sept 24th (Friday), 2021

Expert Speech: The latest progress of IND and NDA review procedures in China

10:05 am - 10:35 am China time, Sept 24th (Friday), 2021

Presenting Companies

Here are our last MSQ Roadshow Event (Jan 28th, 2021) highlights & full summary held at our bi-annual event in Shanghai, China: 2021 Cross-Border Healthcare Innovation & Partnership Summit: Insights and Summary